Loading research and source information…
Condition research
Explore selected studies in early Alzheimer’s disease, prevention in people without cognitive impairment, and Alzheimer’s-related psychosis. The linked record defines who each study includes.
MeSH D000544 · Also indexed as Alzheimer Disease
20 covered studies · 10 enrolling · 2 with posted results
Coverage grows through automated registry checks for relevant drug and biological treatment studies. This is not every trial or available treatment, and source checks do not establish clinical benefit. Enrollment and results counts exclude records whose source checks are overdue or under review. Listed ages are only part of eligibility; the study team must confirm eligibility and availability at your location.
Showing 17–20 of 20 matching studies · Page 3 of 3
Sorted by the registry’s latest update, not our check date. With the enrolling filter, locations must be marked recruiting; other views include sites that may be closed.
US: FDA approval not reviewed here
The registry reports active not recruiting. This is trial metadata, not an assessment of treatment benefit.
Phase 2 · Ongoing, no longer enrolling
Planned enrollment: 164 participants
Study ages: 60 Years and older
No results-posting date in this record
Read trial record and resultsChecked Oct 28, 2026
US: FDA approval not reviewed here
The registry reports completed. This is trial metadata, not an assessment of treatment benefit.
An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects
Phase 3 · Completed
Registry enrollment: 325 participants
Study ages: 50 Years to 80 Years
Results posted Nov 10, 2025
Read trial record and resultsChecked Oct 27, 2026
The registry reports recruiting. This is trial metadata, not an assessment of treatment benefit.
The registry reports recruiting. This is trial metadata, not an assessment of treatment benefit.
US: FDA approval not reviewed here
The registry reports recruiting. This is trial metadata, not an assessment of treatment benefit.
Phase 2 · Enrolling participants
Planned enrollment: 370 participants
Study ages: 55 Years and older
Recruiting sites listed in: Bulgaria, Croatia, Czechia, Italy, Romania and 4 more countries/territories (see details)
No results-posting date in this record
Read trial record and resultsChecked Oct 28, 2026
US: FDA approval not reviewed here
The registry reports active not recruiting. This is trial metadata, not an assessment of treatment benefit.
A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)
Phase 3 · Ongoing, no longer enrolling
Registry enrollment: 1,736 participants
Study ages: 60 Years to 85 Years
Results posted May 20, 2024
Read trial record and resultsChecked Oct 27, 2026
The registry reports completed. This is trial metadata, not an assessment of treatment benefit.
The registry reports active not recruiting. This is trial metadata, not an assessment of treatment benefit.
The registry reports active not recruiting. This is trial metadata, not an assessment of treatment benefit.
The registry reports recruiting. This is trial metadata, not an assessment of treatment benefit.